Market News

Stay updated with the latest market trends, earnings, and economic indicators.

Showing news for:ABBOTINDIAFinancial Services
Clear all filters
NEWS
positive
Business Standard - Markets 5d ago

Abbott India Ltd gains for fifth session

Abbott India Ltd is quoting at Rs 26830, up 3.61% on the day as on 12:44 IST on the NSE. The stock is down 22.2% in last one year as compared to a 3.99% gain in NIFTY and a 15.09% gain in the Nifty Pharma.

ABBOTINDIAAONELIQUIDAONENIFTYAONETMMQ50AONETOTALPHARMABEESFinancial ServicesHealthcare
NEWS
positive
Business Standard - Markets 37d ago

Abbott India Ltd drops for fifth straight session

Abbott India Ltd is quoting at Rs 26020, down 1.03% on the day as on 13:19 IST on the NSE. The stock jumped 5.41% in last one year as compared to a 5.65% slide in NIFTY and a 11.71% spurt in the Nifty Pharma index.

ABBOTINDIAAONELIQUIDAONENIFTYAONETMMQ50AONETOTALBANKIETFPHARMABEESPVTBANIETFFinancial ServicesHealthcare
₹656 Dividend Bonanza: 71,000 retail shareholders of this MNC drugmaker set for their highest payout
positive
CNBC TV18 - Markets 60d ago

₹656 Dividend Bonanza: 71,000 retail shareholders of this MNC drugmaker set for their highest payout

This is the highest dividend payout on record for Abbott India, having surpassed the ₹475 per share it had paid shareholders last year.

ABBOTINDIADIVIDENDMNCRETAILSDREAMSV2RETAILConsumer ServicesFinancial Services
JPMorgan downgrades this drugmaker, cuts price target by 19% citing growth challenges
positive
CNBC TV18 - Markets 87d ago

JPMorgan downgrades this drugmaker, cuts price target by 19% citing growth challenges

Of the eight analysts who have coverage on the Abbott India stock, six have a 'buy' rating, while one each have 'hold' and 'sell' ratings.

ABBOTINDIAAONELIQUIDFinancial ServicesHealthcare
Market Trading Guide: Buy Balrampur Chini and Abbott India on Thursday for gains up to 5%
positive
ET Markets - Stocks 129d ago

Market Trading Guide: Buy Balrampur Chini and Abbott India on Thursday for gains up to 5%

The Nifty fell 1.6% amid broad-based selling triggered by the Iran-Israel conflict, with financials, auto and energy stocks leading losses. Analysts flag weak momentum and advise a sell-on-rise approach, while recommending Balrampur Chini Mills and Abbott India for short-term gains.

ABBOTINDIAABGSECAONETMMQ50AONETOTALAUTOBEESAUTOIETFBALRAMCHINENERGYGKENERGYGROWWMOM50KPELLTGILTBEESMIDSMALLMOCAPITALMOENERGYMOM30IETFMOMENTUMMOMENTUM30MOMENTUM50MOMIDMTMMOMOMENTUMSMALLCAPConstructionFast Moving Consumer Goods
Abbott India to sell Novo Nordisk’s semaglutide, weight-loss drug behind Ozempic
neutral
CNBC TV18 - Markets 134d ago

Abbott India to sell Novo Nordisk’s semaglutide, weight-loss drug behind Ozempic

Abbott India has partnered Novo Nordisk to market semaglutide under the Extensior brand, aiming to tap rising demand for advanced diabetes therapies in one of the world’s fastest-growing markets.

ABBOTINDIAAONETMMQ50AONETOTALFinancial ServicesHealthcare
What sets apart MNC pharma companies from their Indian counterparts
positive
Moneycontrol NaNd ago

What sets apart MNC pharma companies from their Indian counterparts

Dividend payments by Abbott and Pfizer increased significantly in last two fiscal years even as they lag Indian majors in growth

ABBOTINDIADIVIDENDMNCPFIZERFinancial ServicesHealthcare